Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6460]

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Two immunotherapy drug combination offers chemotherapy-free option for advanced NSCLC

ESMO 2019: Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy

ESMO 2019: Liquid biopsy has prognostic role in colorectal cancer and potential for guiding therapy

ESMO 2019: One in two patients with metastatic melanoma alive after five years with combination immunotherapy

ESMO 2019: One in two patients with metastatic melanoma alive after five years with combination immunotherapy

ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary

ESMO 2019: DNA profiling may hold key to better treatment options in carcinoma of unknown primary

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Trial finds high-dose radiation effective for men whose prostate cancer has spread

Semen miRNAs could be non-invasive biomarkers for prostate cancer

Semen miRNAs could be non-invasive biomarkers for prostate cancer

Cancer: The origin of genetic mutations

Cancer: The origin of genetic mutations

Researchers apply fat cells to deliver drug to suppress tumour growth

Researchers apply fat cells to deliver drug to suppress tumour growth

Study finds potential therapeutic target for prostate cancers with PTEN mutation

Study finds potential therapeutic target for prostate cancers with PTEN mutation

More from ecancer